Work

Targeting fibroblast growth factor receptors in head and neck cancers: Identifying therapeutic vulnerabilities for radiochemosensitization and overcoming adaptive resistance

Year: 2025
Type: dissertation
Abstract: Background Head and neck squamous cell carcinoma (HNSCC) remains a critical oncological challenge, particularly in human papillomavirus (HPV)-negative cases. These tumors are characterized by poor patient survival rates and high recurrence rates, attributed mainly to the development of therapy resistances. The mechanisms underlying these resistances are complex and multifactorial, including phenotypic plasticity driven by epithelial-to-mesenchymal transition (EMT), and cooperative pro-survival signaling via receptor tyrosine kinases (RTKs) and integrin adhesion receptors. While dual inhibition of the frequently overexpressed epidermal growth factor receptor (EGFR) and β1 integrin has demonstrated promising preclinical efficacy, non-responsiveness in certain models suggests the involvement of additional oncogenic signaling networks. Hypothesis This study aims to identify novel RTK/β1 integrin-based vulnerabilities in HPV-negative HNSCC. It is hypothesized that combined inhibition of a specific RTK and β1 integrin elicits superior cytotoxic and radiochemosensitizing effects in HPV-negative HNSCC models compared to monotherapy. Furthermore, it is hypothesized that targeting kinases upregulated in response to initial therapy effectively circumvents emerging resistance mechanisms. Methods The cytotoxic and radiochemosensitizing efficacy of targeting 10 distinct RTKs, alone or in conjunction with β1 integrin, was evaluated in up to 20 three-dimensional laminin-rich extracellular matrix (3D lrECM)-cultured HNSCC cell models. RNA interference and pharmacological-based targeting approaches were utilized in cell viability and clonogenic survival assays complemented by single doses of 6 Gy X-rays and/or cisplatin treatment. Molecular profiling was performed by RNA sequencing and protein-based biochemical assays. Cell viability-based drug screening with 36 kinase inhibitors was employed to identify resistance-deactivating targets. Clinical relevance was assessed by transferring the resistance signature to HPV-negative HNSCC cohorts using machine learning and pathway analysis. Network analyses integrating drug screening and clinical cohort data were conducted to identify key determinants of resistance. Results Among the examined RTKs, depletion of the fibroblast growth factor receptor (FGFR) family exhibited the most pronounced cytotoxic and radiosensitizing effects. Dual pharmacological targeting, using the pan-FGFR inhibitor erdafitinib (FGFRi) and the anti-β1 integrin antibody AIIB2, enhanced radiochemosensitization across a heterogeneous panel of HNSCC cell models. However, a subset of models exhibited a profound radioprotective resistance to FGFRi. Transcriptomic analyses revealed that FGFRi treatment elicited mesenchymal-to-epithelial transition (MET) in sensitive UT-SCC 33 cells, whereas FGFRi-induced resistance in UM-SCC 10a cells was associated with an EGFR-driven partial EMT (pEMT) phenotype. Mechanistically, a feedback loop involving ERK1/2 hyperphosphorylation upon FGFR3 deactivation was implicated in this adaptive pEMT resistance. Kinase inhibitor screening confirmed that EGFR inhibition effectively abrogated FGFRi resistance in UM-SCC 10a cells. Additionally, novel kinase targets, including Fyn, PAK1-3, and PKCα, were identified, demonstrating the capacity to either reverse FGFRi resistance or enhance FGFRi efficacy in other HNSCC models. Transferring the pEMT-related resistance signature to patient cohorts confirmed its prognostic significance and highlighted overexpressed and druggable genes, including PLAU, HBEGF, and ITGA5. Integrating drug screening and clinical signature results into network analyses underscored their close interconnection and emphasized the central role of EGFR as a key mediator of pEMT-related resistance, thus offering targetable vulnerabilities for therapeutic intervention. Conclusions This study highlights the therapeutic potential of targeting the FGFR family in HPV-negative HNSCC, while also revealing the risk of adaptive resistance. FGFR inhibition induced a spectrum of responses, ranging from beneficial radiochemosensitization, enhanced by concurrent β1 integrin blockade, to pronounced cyto- and radioprotective effects. Notably, the dynamics of EMT were significantly influenced by FGFRi treatment across this spectrum. The adaptive pEMT-related resistance appears to be of clinical significance and can be therapeutically exploited through rational combination strategies targeting FGFR, EGFR, and associated kinases. As FGFR inhibitors gain clinical traction in other cancer types, further investigation into predictive biomarkers and adaptive resistance mechanisms will be essential for their optimal application in HNSCC. The identified FGFRi resistance network provides a foundation for the development of personalized and adaptable therapeutic approaches aimed at achieving durable treatment responses in HNSCC.
Author: Broghammer, Felix
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7114823811
Cites: 442
Cited by:
Related to: 10